Bio Essence Corp (BIOE) income statement
BIOEOTCPharmaceutical PreparationsFiscal year ends December 31
$0.42+0.03 (+7.72%)
Close on Oct 19, 2026Market cap $22.70MP/E 10.5Yield –
Bio Essence Corp financial ratios
See a number that looks wrong?
Close on Oct 19, 2026Market cap $22.70MP/E 10.5Yield –
See a number that looks wrong?
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Margins | |||||||
| Gross margin | 75.3% | 67.0% | 50.3% | 52.8% | 33.6% | 23.7% | – |
| Operating margin | 47.4% | -141.8% | -62.7% | -82.2% | -96.6% | -86.8% | – |
| EBITDA margin | 47.4% | -141.5% | -61.8% | -79.9% | -92.5% | -83.4% | – |
| Pre-tax margin | 47.3% | -483.1% | -73.1% | -84.5% | -72.6% | -61.8% | – |
| Net profit margin | 47.2% | -404.0% | -176.2% | -130.3% | -72.9% | -62.2% | – |
| Free cash flow margin | – | – | -186.6% | -113.7% | -159.2% | -77.2% | – |
| Effective tax rate | 0.09% | – | – | – | – | – | – |
| Returns on capital | |||||||
| Return on equity | -35.5% | 56.5% | 39.7% | 28.6% | 30.8% | 41.6% | – |
| Return on assets | 254.8% | -86.1% | -45.1% | -49.9% | -36.5% | -32.3% | – |
| Return on tangible assets | 254.9% | -86.1% | -45.1% | -49.9% | -36.6% | -32.4% | – |
| Return on capital employed | -39.7% | 41.5% | 40.6% | 33.3% | 155.0% | 1,685.2% | – |
| NOPAT | $899.21K | -$362.96K | -$273.02K | -$403.80K | -$677.45K | -$657.73K | – |
| Cash flow quality | |||||||
| OCF / Sales | 82.7% | 192.6% | -186.0% | -113.1% | -145.7% | -76.4% | – |
| OCF / Net income | 1.75 | -0.48 | 1.06 | 0.87 | 2.00 | 1.23 | – |
| FCF / OCF | – | – | 100.4% | 100.5% | 109.2% | 101.0% | – |
| FCF / Net income | – | – | 1.06 | 0.87 | 2.18 | 1.24 | – |
| FCF / EBITDA | – | – | 302.0% | 142.4% | 172.0% | 92.6% | – |
| Unlevered free cash flow | – | – | -$1.03M | -$695.82K | -$1.38M | -$707.01K | – |
| Levered free cash flow | – | – | -$1.03M | -$706.98K | -$1.41M | -$740.11K | – |
| Efficiency | |||||||
| Asset turnover | 5.39 | 0.21 | 0.26 | 0.38 | 0.50 | 0.52 | – |
| Fixed asset turnover | – | – | 4.41 | 2.91 | 6.50 | 10.37 | – |
| Receivables turnover | 132.80 | 16.11 | 27.11 | 55.45 | 28.69 | 21.27 | – |
| Days sales outstanding | 2.7 | 22.7 | 13.5 | 6.6 | 12.7 | 17.2 | – |
| Payables turnover | 14.30 | 7.08 | 8.81 | 5.22 | 10.44 | 14.52 | – |
| Days payables outstanding | 25.5 | 51.6 | 41.4 | 69.9 | 35.0 | 25.1 | – |
| Inventory turnover | – | – | 1.69 | 1.49 | 2.43 | 2.69 | – |
| Days inventory outstanding | – | – | 216.0 | 245.3 | 150.2 | 135.9 | – |
| Operating cycle | – | – | 229.5 | 251.9 | 162.9 | 153.0 | – |
| Cash conversion cycle | – | – | 188.1 | 181.9 | 127.9 | 127.9 | – |
| CapEx to revenue | – | – | 0.66% | 0.60% | 13.5% | 0.77% | – |
| CapEx to OCF | – | – | -0.35% | -0.53% | -9.2% | -1.0% | – |
| CapEx to depreciation | – | – | 0.75 | 0.26 | 3.34 | 0.22 | – |
| Liquidity | |||||||
| Current ratio | 0.17 | 0.10 | 0.12 | 0.06 | 0.10 | 0.17 | – |
| Quick ratio | 0.17 | 0.10 | 0.06 | 0.01 | 0.02 | 0.03 | – |
| Cash ratio | – | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | – |
| Working capital | -$2.02M | -$2.52M | -$2.15M | -$3.35M | -$2.49M | -$1.57M | – |
| Net current asset value | -$2.07M | -$2.97M | -$4.12M | -$4.58M | -$3.87M | -$3.30M | – |
| Leverage | |||||||
| Assets to equity | -0.20 | -0.09 | -1.66 | -0.48 | -0.70 | -1.04 | – |
| Intangibles to total assets | 0.02% | 0.12% | 0.02% | 0.05% | 0.06% | 0.40% | – |
| Interest coverage | |||||||
| EBIT / Interest expense | 411.72 | -213.39 | -157.30 | -36.17 | -22.24 | -19.87 | – |
| EBITDA / Interest expense | 411.82 | -212.97 | -155.12 | -35.14 | -21.31 | -19.08 | – |
| (EBITDA − CapEx) / Interest expense | – | – | -156.76 | -35.41 | -24.41 | -19.25 | – |
| Per share | |||||||
| Revenue per share | 0.05 | 0.0085 | 0.01 | 0.02 | 0.03 | 0.03 | – |
| EPS (basic) | – | -0.03 | -0.03 | -0.02 | -0.02 | -0.02 | – |
| EPS (diluted) | – | -0.03 | -0.03 | -0.02 | -0.02 | -0.02 | – |
| Book value per share | -0.05 | -0.08 | -0.04 | -0.10 | -0.07 | -0.05 | – |
| Tangible book value per share | -0.05 | -0.08 | -0.04 | -0.10 | -0.07 | -0.05 | – |
| Cash per share | – | 0.0000 | 0.0000 | 0.0002 | 0.0000 | 0.0002 | – |
| Operating cash flow per share | 0.04 | 0.02 | -0.03 | -0.02 | -0.04 | -0.02 | – |
| Free cash flow per share | – | – | -0.03 | -0.02 | -0.04 | -0.02 | – |
| CapEx per share | – | – | 0.0001 | 0.0001 | 0.0036 | 0.0002 | – |
| Valuation at period end | |||||||
| Market cap | $2.28M | $9.16M | – | – | – | – | – |
| Enterprise value | $2.25M | $9.13M | – | – | – | – | – |
| P/E | 2.5x | – | – | – | – | – | – |
| P/S | 1.2x | 28.3x | – | – | – | – | – |
| P/B | -1.1x | -3.1x | – | – | – | – | – |
| P/TBV | -1.1x | -3.1x | – | – | – | – | – |
| P/Gross profit | 1.6x | 42.2x | – | – | – | – | – |
| P/OCF | 1.5x | 14.7x | – | – | – | – | – |
| EV/Sales | 1.2x | 28.2x | – | – | – | – | – |
| EV/Gross profit | 1.6x | 42.1x | – | – | – | – | – |
| EV/EBITDA | 2.5x | – | – | – | – | – | – |
| EV/EBIT | 2.5x | – | – | – | – | – | – |
| EV/OCF | 1.4x | 14.6x | – | – | – | – | – |
| Earnings yield | 39.3% | -14.3% | – | – | – | – | – |
| Shareholder yield | |||||||
| Debt paydown yield | – | 0.01% | – | – | – | – | – |
| Cost structure | |||||||
| Stock-based comp to revenue | – | – | – | – | – | 0.93% | – |
| Per employee | |||||||
| Total employees | 4 | 2 | 12 | 11 | 15 | 11 | 11 |
| Revenue per employee | $474.39K | $161.97K | – | $56.51K | $59.20K | $87.15K | – |
| Gross profit per employee | $357.10K | $108.54K | $23.12K | $29.85K | $19.89K | $20.66K | – |
| Operating profit per employee | $225.00K | -$229.72K | -$28.80K | -$46.47K | -$57.17K | -$75.69K | – |
| Net income per employee | $224.05K | -$654.40K | -$80.99K | -$73.61K | -$43.17K | -$54.17K | – |
| Free cash flow per employee | – | – | -$85.77K | -$64.27K | -$94.24K | -$67.28K | – |
| Growth | |||||||
| Revenue 1Y growth | 485.8% | -41.3% | -11.3% | -30.0% | -7.4% | – | – |
| Revenue 3Y CAGR | 45.1% | -28.5% | -16.8% | – | – | – | – |
| Revenue 5Y CAGR | 14.6% | – | – | – | – | – | – |
| Gross profit 1Y growth | 558.0% | -21.8% | -15.5% | 10.1% | 31.3% | – | – |
| Gross profit 3Y CAGR | 63.2% | -10.1% | 6.9% | – | – | – | – |
| Gross profit 5Y CAGR | 44.4% | – | – | – | – | – | – |
| EBIT 1Y growth | 295.9% | -32.9% | 32.4% | 40.4% | -3.0% | – | – |
| EBITDA 1Y growth | 296.3% | -34.5% | 31.4% | 39.6% | -2.8% | – | – |
| Net income 1Y growth | 168.5% | -34.7% | -20.0% | -25.0% | -8.7% | – | – |
| Diluted EPS 1Y growth | – | 0.00% | -50.0% | 0.00% | 0.00% | – | – |
| Operating cash flow 1Y growth | 151.6% | 160.8% | -45.8% | 45.7% | -76.6% | – | – |
| Free cash flow 1Y growth | – | – | -45.6% | 50.0% | -91.0% | – | – |
| CapEx 1Y growth | – | – | -3.4% | -96.9% | 1,522.5% | – | – |
| CapEx 3Y CAGR | – | – | -21.1% | – | – | – | – |
| Total assets 1Y growth | 50.3% | -89.8% | 78.2% | -8.9% | -7.9% | – | – |
| Total assets 3Y CAGR | -35.1% | -45.1% | 14.3% | – | – | – | – |
| Total assets 5Y CAGR | -25.5% | – | – | – | – | – | – |
| Total equity 1Y growth | 30.2% | -78.8% | 48.7% | -33.3% | -36.4% | -64.1% | – |
Every figure here is calculated from standardized financial statements — hover a row name for the formula — not reported by the company. Valuation multiples use the closing price at the end of that period, not today's price.